neutrophil activation multistep process vitro activation neutrophils semiphysiological activators optimal preactivation priming cytokines chemotaxins bacterial products antibodies developed distinguish resting cytokine primed neutrophils sufficient dynamic range necessary screening clinical samples isolated human phage antibodies designated mophab a17 a27 synthetic bacteriophage antibody library phage antibodies recognize epitopes upregulated neutrophils present blood treated low priming concentrations cytokines induction optimal concentrations sufficient priming functional responses neutrophils NUMBER pm NUMBER pmns isolated peripheral blood chronic obstructive pulmonary disease copd patients clinical exacerbation exhibited partial vivo primed phenotype antibodies promise ideal tool monitor disease activity blood patients inflammatory diseases gm csf tnf alpha time concentration dependent gm csf tnf alpha iu ml